YM155 (Synonyms: Sepantronium bromide) |
|
カタログ番号GC13107
|
YM155はimidazoliumに基づいた低分子化合物であり、survivinプロモーターの活性を有力に阻害し、IC50値は0.54nMである。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 781661-94-7
Sample solution is provided at 25 µL, 10mM.
YM155はimidazoliumに基づいた低分子化合物であり、survivinプロモーターの活性を有力に阻害し、IC50値は0.54nMである[1]。YM155は、SP1とsurvivinの核心的なプロモーターとの結合、ILF3–p54/nrb複合体を破壊することで、survivinの発見を抑制できる[2]。YM155は、様々な細胞と動物モデルで、腫瘍細胞アポトーシスの誘発、腫瘍退縮の促進に広く使われる[3]。
体外で、120時間のYM155の処理は、UKF-NB-3とUKF-NB-6細胞の増殖を著しく阻害し、IC50値はそれぞれ0.49と0.65nMであった[4]。40nMのYM155でH1299細胞を24時間処理した結果、細胞死を著しく誘発し、ミトコンドリア機能障害を促進し、トリカルボン酸(TCA)回路中間体を減らした[5]。10nM YM155の24時間の処理は、PANC-1細胞の生存率を著しく阻害し、PANC-1細胞で、PI3K、p-ERKとp-STAT3の下方制御を誘発した[6]。
体内で、2 mg/kg/日のYM155の21日間の皮下注射は、マウスのSH-SY5Y細胞異種移植モデルで、腫瘍の成長を著しく減らし、体重を影響しなかった[7]。YM155 (5mg/kg/日)の21日間の連続的な皮下注射は、原発性滲出性リンパ腫 (PEL)異種移植マウスで、腹水の発生を著しく阻害した[8]。
References:
[1] Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts[J]. Cancer research, 2007, 67(17): 8014-8021.
[2] Rauch A, Hennig D, Schäfer C, et al. Survivin and YM155: how faithful is the liaison?[J]. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2014, 1845(2): 202-220.
[3] Tolcher A W, Quinn D I, Ferrari A, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer[J]. Annals of oncology, 2012, 23(4): 968-973.
[4] Voges Y, Michaelis M, Rothweiler F, et al. Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance[J]. Cell death & disease, 2016, 7(10): e2410-e2410.
[5] Mondal A, Jia D, Bhatt V, et al. Ym155 localizes to the mitochondria leading to mitochondria dysfunction and activation of AMPK that inhibits BMP signaling in lung cancer cells[J]. Scientific reports, 2022, 12(1): 13135.
[6] Na Y S, Yang S J, Kim S M, et al. YM155 induces EGFR suppression in pancreatic cancer cells[J]. PloS one, 2012, 7(6): e38625.
[7] Li X, Yang F, He N, et al. YM155 inhibits neuroblastoma growth through degradation of MYCN: A new role as a USP7 inhibitor[J]. European Journal of Pharmaceutical Sciences, 2023, 181: 106343.
[8] Kojima Y, Hayakawa F, Morishita T, et al. YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma[J]. Pharmacological research, 2017, 120: 242-251.
| 細胞実験[1]: | |
細胞株 | PC-3細胞 |
準備方法 | 10%の熱不活性化のウシ胎児血清を添加したDMEM培地で、PC-3細胞を培養し、37℃、5% CO2の湿潤インキュベーターに播種した。YM155 (1、10、100と1000nM)の存在下で、48時間培養した後、PC-3細胞をトリプシンの消化と遠心分離で採取し、DMEM培地で再懸濁した。細胞懸濁液を等量のトリパンブルー(0.4%の作業溶液)で希釈した。生細胞(未染色)と死亡(染色)した細胞を血球カウンターで数えた。 |
反応条件 | 1、10、100と1000nM;48時間 |
アプリケーション | YM155は、PC-3細胞の生存率を用量依存的に著しく阻害した。 |
| 動物実験 [2]: | |
動物モデル | 雌のBALB/c-nuマウス |
準備方法 | 6週齢の雌のBALB/c-nuマウスを標準殺菌環境で飼育した。SH-SY5Y細胞(2×106)を採取し、等量のMatrigelと混合し、マウスの脇腹に皮下注射した。腫瘍形成後、マウスをランダムに二つのグループに分けた:溶媒群(生理食塩水)またはYM155群。微浸透圧ポンプを使い、2mg/kg/日のYM155を21日間連続的に皮下注射した。腫瘍の直径を週に二回測定し、腫瘍の体積を、長さ× 幅2×0.5として算出した。 |
投与形態 | 2mg/kg/日、21日間;皮下注射 |
アプリケーション | YM155の処理は、マウスのSH-SY5Y細胞異種移植モデルで、腫瘍の成長を著しく減らした。 |
References: | |
| Cas No. | 781661-94-7 | SDF | |
| 同義語 | Sepantronium bromide | ||
| Chemical Name | 1-(2-methoxyethyl)-2-methyl-3-(pyrazin-2-ylmethyl)benzo[f]benzimidazol-3-ium-4,9-dione;bromide | ||
| Canonical SMILES | CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-] | ||
| Formula | C20H19BrN4O3 | M.Wt | 443.3 |
| 溶解度 | ≥ 22.15 mg/mL in DMSO, ≥ 13.49 mg/mL in EtOH with ultrasonic, ≥ 96.2 mg/mL in Water with ultrasonic | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2558 mL | 11.279 mL | 22.5581 mL |
| 5 mM | 451.2 μL | 2.2558 mL | 4.5116 mL |
| 10 mM | 225.6 μL | 1.1279 mL | 2.2558 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)















